Dr John Tchelingerian becomes Chairman of Promethera Biosciences

Biotech entrepreneur brings scientific, dealmaking and commercial experience to the team

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, has announced that Dr John Tchelingerian has joined the company as Chairman of the Board. He comes to the company as it is gearing up to launch a Phase IIb/III trial in Europe and assess new indications.

Tchelingerian is a serial entrepreneur and a private investor. He has co-founded and managed several biotech companies including Neurotech, Key-Obs and Diatos.

In the past 10 years he has raised over US$100m (€81m) for his entrepreneurial ventures from venture capitalists and private equity sources in Europe, the US and Japan. He has also closed several biotech and pharma partnering deals.

You may also like

Research & Development

EMD Millipore to collaborate with Promethera Biosciences

Promethera to use microfluidic system from Millipore for liver disease research
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Subscribe now